APA (7th ed.) Citation

LJ, C., FE, D., GP, M., T, K., N, B., A, J., . . . EA, S. (2021). Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma. Blood advances, 5(19), 3748. https://doi.org/10.1182/bloodadvances.2020004146

Chicago Style (17th ed.) Citation

LJ, Costa, et al. "Phase 2 Study of Venetoclax Plus Carfilzomib and Dexamethasone in Patients with Relapsed/refractory Multiple Myeloma." Blood Advances 5, no. 19 (2021): 3748. https://doi.org/10.1182/bloodadvances.2020004146.

MLA (9th ed.) Citation

LJ, Costa, et al. "Phase 2 Study of Venetoclax Plus Carfilzomib and Dexamethasone in Patients with Relapsed/refractory Multiple Myeloma." Blood Advances, vol. 5, no. 19, 2021, p. 3748, https://doi.org/10.1182/bloodadvances.2020004146.